Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Prognostic Stratification of the IMDC Intermediate Risk Group After ...
CART-Tree analysis for overall survival in IMDC intermediate risk group ...
Kaplan-Meier overall survival curves in intermediate IMDC risk patients ...
Table I. | Prognostic Stratification of the IMDC Intermediate Risk ...
Table III. | Prognostic Stratification of the IMDC Intermediate Risk ...
ASCO 2019: Update on the CARMENA Trial with Focus on Intermediate IMDC ...
TTNT according to the IMDC risk category. IMDC 0, favorable risk; IMDC ...
Overall survival according to the IMDC risk category. IMDC 0, favorable ...
ASCO GU 2023: Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial ...
ASCO-GU 2023: Outcomes by IMDC risk in the COSMIC-313 phase 3 trial ...
EAU 2024: Does Scalpel Play a Role in Intermediate Risk Metastatic RCC? dCN
Risk Group According to MSKCC and IMDC Scales | Download Scientific Diagram
Figure S1 Overall survival according to IMDC risk group and PS absence ...
MSKCC and IMDC risk group classification based on a complete case and ...
Risk factors included in the MSKCC and IMDC prognostic models. Patients ...
CheckMate 214: Outcomes in the IMDC Intermediate/Poor Risk Groups and ...
Flowchart for the selection of the study population. IMDC risk score ...
Comparison between the Meet-URO prognostic score and IMDC risk groups ...
Distribution of risk factors according to IMDC criteria in the study ...
Median OS estimates in first-and second-line RCC according to IMDC risk ...
Emory risk group versus IMDC risk group stratification and association ...
External Validation of the MSKCC and IMDC Risk Models in Patients ...
PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate ...
Infographic: Understanding IMDC criteria - IKCC - International Kidney ...
Risk assessment for metastatic renal cell carcinoma according to the ...
The Metastatic Renal Cancer Database Consortium (IMDC) risk model [440 ...
Subgroup Analysis of Overall Survival among IMDC Intermediate-and ...
Progression-free survival per investigator assessment in IMDC ...
Risk Stratification and Treatment Algorithm of Metastatic Renal Cell ...
Overall survival amongst Japanese IMDC intermediate/poor-risk patients ...
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC ...
Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC ...
EAU 2025: State-of-the-art Lecture: Risk Stratification for Patients ...
Real-world data on the efficacy and safety of pazopanib in IMDC ...
Health-Related Quality of Life in IMDC Intermediate-and Poor-Risk ...
Progression-free survival per investigator amongst Japanese IMDC ...
Change in target tumour burden over time in IMDC intermediate/poor-risk ...
Validation of the IMDC Prognostic Model in Patients With Metastatic ...
Overall survival by (A) overall population and (B) the IMDC group. IMDC ...
Reclassifi cation calibration comparing the IMDC model with the MSKCC ...
OS stratified by IMDC score (12-month OS 43.2% in poor vs. 77.2% in ...
Impact of Disagreement Between Two Risk Group Models on Prognosis in ...
FDA Approves OPDIVO® plus YERVOY® Combination Immunotherapy for ...
Renal cancer: management - The Pharmaceutical Journal
Overview of treatment strategy for treatment naïve metastatic RCC ...
Overall survival; Kaplan-Meier estimates for OS in (a) full population ...
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in aRCC
ASCO 2025: Gut-Associated Checkpoint as a Prognostic Biomarker in ...
Current therapeutic recommendations for clear cell renal cell cancer ...
PPT - CheckMate 214: Revolutionizing Renal Cancer Treatment PowerPoint ...
Full article: Real-World Outcomes in Patients with Metastatic Renal ...
Updated European Association of Urology Guidelines on Renal Cell ...
First-line Therapy: Intermediate-/Poor-Risk RCC - Slideset Download ...
Forest plot of the indirect comparison between each combination. (A ...
Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus | OTT
ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab ...
Overall Survival and Progression-free Survival among IMDC... | Download ...
ASCO 2019: Pembrolizumab Plus Axitinib versus Sunitinib as First-Line ...
Oncotarget: Identification intermediate-risk subgroups in metastatic ...
ASCO 2023: The Role of Cytoreductive Nephrectomy and Surgical ...
Real-world Assessment of Clinical Outcomes in Patients with Metastatic ...
Renal Cell Carcinoma - DISEASE MANAGEMENT - Uroweb
Recommendations for the management of advanced and metastatic renal ...
Prognostic significance of 18F-FDG PET/CT indices in metastatic renal ...
Kaplan–Meier cumulative survival of patients with primary metastatic ...
ESMO 2022: Phase 3 Study of Cabozantinib in Combination With Nivolumab ...
mRCC presentation.pptx
Advanced Kidney Cancer
Preferred treatment choice in fit and unfit, IMDC... | Download ...
European Association of Urology Guidelines on Renal Cell Carcinoma: The ...
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the ...
OS in chrRCC vs clear cell mRCC. | Download Scientific Diagram
ASCO 2018: Prognostic Biomarkers in the "Precise" Management of Kidney ...
Platelet Counts May Refine Classification of Renal-Cell Carcinoma ...
Differences in PFS benefit associated with immune-based combinations in ...
ASCO 2019: Pembro plus Axitinib vs Sunitinib as First-Line Therapy for ...
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell ...
Differences in OS benefit associated with immune-based combinations in ...
Metastatic renal cell carcinoma | PPTX
Frontiers | Biomarkers of Prognosis and Efficacy of Anti-angiogenic ...
ASCO GU 2025: Case-Based Session: Failure of Immunotherapy in Renal ...
CheckMate-9ER Update: Survival Better With First-Line Nivolumab ...
Optimizing Treatment Approaches in Advanced Renal Cancer
ASCO 2025: Nivolumab plus Ipilimumab vs Sunitinib for First-Line ...
The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving ...
ASCO GU 2025: Real-World Outcomes of First-Line Dual Immunotherapy ...
